Clinical Trial Update: Dose Escalation Study With 99mTC - or 186 Re-labelled Humanised Monoclonal Antibody (hMAb) BIWA 4 in Patients With Head and Neck Cancer [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of BIWA 4, a radiolabeled humanised monoclonal antibody, using 99mTc or 186Re labeling in patients with head and neck cancer; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• BIWA 4 (99mTc- or 186Re-labeled humanised monoclonal antibody) (BIWA-4)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Head and Neck Neoplasms | Phase 1 | Status: COMPLETED